First report from a single center retrospective study in Kazakhstan on acute myeloid leukemia treatment outcomes
Kulkayeva G.U. Kemaykin V.M. Kuttymuratov A.M. Burlaka Z.I. Saparbay J.Z. Zhakhina G.T. Adusheva A.A. Dosayeva S.D.
December 2021Nature Research
Scientific Reports
2021#11Issue 1
Acute myeloid leukemia (AML) is the most common hematological malignancy in adults. In the last decade, internationally approved AML treatment guidelines, including hematopoietic stem cell transplantation are widely used in Kazakhstan. The categorization of acute myeloid leukemia was done according to the French-American British classification. The prognosis of patients at the time of diagnosis was determined by cytogenetic tests following the guidelines of the European LeukemiaNet. The overall survival and event-free survival were analyzed using the Kaplan–Meier method, and hazard ratios were defined with Cox regression. In total, 398 patients with AML were treated in the National Research Oncology Center between 2010 and 2020. The mean age was 38.3 years. We found a correlation between ethnicity, cytogenetic group, white blood cell count, and treatment approaches with overall and event-free survival. There was a significantly longer OS in a cytogenetic group with a good prognosis compared with intermediate and poor prognosis. The median survival time in the group with a good prognosis was 43 months, 23 months in the intermediate group (p = 0.7), and 12 months in the poor prognosis group (p = 0.016). There was a significantly longer OS for the group of patients who received hematopoietic stem cell transplantation (HSCT), 52 months versus 10 months in the group who received chemotherapy only, p-value < 0.0001. Prognostic factors, such as cytogenetic group, initial WBC count, and treatment approaches are significantly associated with patient survival. Our study data were consistent with the most recent studies, available in the literature adjusted for the population in question.
Text of the article Перейти на текст статьи
LLP «National Research Oncology Center», Kerey and Zhanibek Khandar Street 3, Nur-Sultan, 01-0000, Kazakhstan
Department of Oncohematology and Stem Cell Transplantation, LLP «National Research Oncology Center», Kerey and Zhanibek Khandar Street 3, Nur-Sultan, 01-0000, Kazakhstan
Department of Hepatology, Gastroenterology and Organ Transplantation, LLP «National Research Oncology Center», Kerey and Zhanibek Khandar Street 3, Nur-Sultan, 01-0000, Kazakhstan
Department of Science, LLP «National Research Oncology Center», Kerey and Zhanibek Khandar Street 3, Nur-Sultan, 01-0000, Kazakhstan
LLP «National Research Oncology Center»
Department of Oncohematology and Stem Cell Transplantation
Department of Hepatology
Department of Science
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026